Blog

Sep 5, 2021

Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia

Posted by in category: biotech/medical

Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r/r) T-cell acute lymphoblastic (ALL), a first-in-human clinical trial showed.

After a median follow-up of 6.3 months, 15 of the 18 responding patients remained in remission, and seven patients had undergone stem-cell transplantation (SCT). All patients developed cytokine release syndrome (CRS), which was grade 1/2 in most instances. Because the therapy involved unmanipulated T cells, a majority of patients developed graft-versus-host disease (GVHD), grade 1/2 severity in all cases. All of the patients developed severe cytopenias, which were manageable.

The results provided the basis for an ongoing phase II trial of the donor-derived anti-CD7 therapy, reported Jing Pan, MD, of the State Key Laboratory of Experimental Hematology and Beijing Boren Hospital in China, and colleagues in the Journal of Clinical Oncology.

Comments are closed.